Enhertu® (fam-trastuzumab deruxtecan-nxki) – New drug approval
December 20, 2019 - The FDA announced the approval of Daiichi Sankyo’s Enhertu (fam-trastuzumab deruxtecan-nxki), for the treatment of adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.
Top